Versatope Therapeutics Inc
CAGE Code: 7TEE7
NCAGE Code: 7TEE7
Status: Active
Type: Commercial Supplier
Summary
Versatope Therapeutics Inc is an Active Commercial Supplier with the Cage Code 7TEE7.
Address
110 Canal St
Fl 4
Lowell MA 01852-4574
United States
Points of Contact
- Telephone:
- 7818793119
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Shipley Motor Equipment Company Reboot Medical Inc. Project Learn, Inc. Savage Jr Neil J Searles, Asa Rl Cleaning Group Inc Central Research Inc Tri-Creek Ambulance Service Agency, Tackett, James Nrgtree, Llc Lowell Fire Department Captivate, Llc King Printing Company, Inc. Cherry Ridge Juice Recoveralife Inc Origo Automation, Inc. Lgr 1, Inc. Small Steps Daycare, Inc. Kimball & Thompson Produce Company Harold Zeigler Ford, Inc.
Frequently Asked Questions (FAQ) for CAGE 7TEE7
- What is CAGE Code 7TEE7?
- 7TEE7 is the unique identifier used by NATO Organizations to reference the physical entity known as Versatope Therapeutics Inc located at 110 Canal St, Fl 4, Lowell MA 01852-4574, United States.
- Who is CAGE Code 7TEE7?
- 7TEE7 refers to Versatope Therapeutics Inc located at 110 Canal St, Fl 4, Lowell MA 01852-4574, United States.
- Where is CAGE Code 7TEE7 Located?
- CAGE Code 7TEE7 is located in Lowell, MA, USA.
Contracting History for CAGE 7TEE7 Most Recent 25 Records
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 28 Sep 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,188,165.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Make An Award Under Hhs-Nih-Niaid-Baa2018
- 4 Sep 2019
- To Make An Award Under Hhs-Nih-Niaid-Baa2018
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,577,945.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 6 May 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 4 Dec 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,191,018.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 10 Sep 2021
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 22 Aug 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,188,165.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- Eo14042 - To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 25 Oct 2021
- Eo14042 - To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 12 Apr 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $9,102,819.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 6 Jun 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,793,945.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 3 Jul 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $9,102,819.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- 9 Jan 2020
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,577,945.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 7 Mar 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,401,888.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 30 Aug 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $11,593,884.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 13 Sep 2023
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $12,191,018.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 18 Nov 2022
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $8,188,165.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- 9 Dec 2021
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate The Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,295,169.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00060
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- 6 Feb 2020
- To Advance The Lead Universal Influenza Vaccine Candidate Through A Phase I Clinical Study And To Evaluate Safety And Long-Term Immunogenicity With One And / Or Two Immunizations.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,577,945.00
- Department Of Health And Human Services (Hhs)